Real-world assessment of myelodysplastic syndrome: Japanese claims data analysis.
Future Oncol
; 18(1): 93-104, 2022 Jan.
Article
em En
| MEDLINE
| ID: mdl-34652217
ABSTRACT
Aim:
To describe the treatment landscape and associated economic burden for myelodysplastic syndrome in Japan.Methods:
We studied nationwide retrospective claims data from 2008 to 2019. The study cohort was categorized into patients receiving transfusion, erythropoiesis-stimulating agent, erythropoiesis-stimulating agent + transfusion, azacitidine, azacitidine + transfusion and others.Results:
Our study found that the azacitidine + transfusion group had the highest medical cost and severity of disease compared with the other groups. In those patients, healthcare resource utilization and the costs of transfusions, including iron chelation therapy, increased medical costs.Conclusion:
Our retrospective analysis provides a current snapshot of real-world treatment patterns and associated incremental economic costs of iron chelation therapy with the presence of transfusions that drive an increase in total costs.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
1_ASSA2030
Base de dados:
MEDLINE
Assunto principal:
Síndromes Mielodisplásicas
Tipo de estudo:
Observational_studies
Limite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2022
Tipo de documento:
Article